These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 10498216

  • 1. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
    Lavergne O, Harnett J, Rolland A, Lanco C, Lesueur-Ginot L, Demarquay D, Huchet M, Coulomb H, Bigg DC.
    Bioorg Med Chem Lett; 1999 Sep 06; 9(17):2599-602. PubMed ID: 10498216
    [Abstract] [Full Text] [Related]

  • 2. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor.
    Demarquay D, Coulomb H, Huchet M, Lesueur-Ginot L, Camara J, Lavergne O, Bigg D.
    Ann N Y Acad Sci; 2000 Sep 06; 922():301-2. PubMed ID: 11193906
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synthesis of 9-(heteroarylmethylidene)amino derivatives of homocamptothecin with biological activities.
    Guo W, Miao Z, Sheng C, Yao J, Liu W, Zhu L, Zhang Y, Cheng P, Dong G, Zhuang C, Zhang W.
    Chem Biodivers; 2011 Jul 06; 8(7):1266-73. PubMed ID: 21766447
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.
    Demarquay D, Huchet M, Coulomb H, Lesueur-Ginot L, Lavergne O, Kasprzyk PG, Bailly C, Camara J, Bigg DC.
    Anticancer Drugs; 2001 Jan 06; 12(1):9-19. PubMed ID: 11272292
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and cytotoxicity of novel 20-O-linked homocamptothecin ester derivatives as potent topoisomerase I inhibitors.
    Li DZ, Wang CY, Liu RH, Wang YM, Ji TF, Li YR, Pan XD.
    J Asian Nat Prod Res; 2013 Nov 06; 15(11):1179-88. PubMed ID: 24215541
    [Abstract] [Full Text] [Related]

  • 8. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
    Bailly C, Laine W, Baldeyrou B, Demarquay D, Huchet M, Coulomb H, Lanco C, Lavergne O, Bigg DC.
    Anticancer Drug Des; 2001 Feb 06; 16(1):27-36. PubMed ID: 11762642
    [Abstract] [Full Text] [Related]

  • 9. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
    Huchet M, Demarquay D, Coulomb H, Kasprzyk P, Carlson M, Lauer J, Lavergne O, Bigg D.
    Ann N Y Acad Sci; 2000 Feb 06; 922():303-5. PubMed ID: 11193907
    [No Abstract] [Full Text] [Related]

  • 10. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
    Liu W, Zhu L, Guo W, Zhuang C, Zhang Y, Sheng C, Cheng P, Yao J, Wang W, Dong G, Wang S, Miao Z, Zhang W.
    Eur J Med Chem; 2011 Jun 06; 46(6):2408-14. PubMed ID: 21463912
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Antitumor agents 216. Synthesis and evaluation of paclitaxel-camptothecin conjugates as novel cytotoxic agents.
    Ohtsu H, Nakanishi Y, Bastow KF, Lee FY, Lee KH.
    Bioorg Med Chem; 2003 Apr 17; 11(8):1851-7. PubMed ID: 12659771
    [Abstract] [Full Text] [Related]

  • 14. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
    Urasaki Y, Takebayashi Y, Pommier Y.
    Cancer Res; 2000 Dec 01; 60(23):6577-80. PubMed ID: 11118036
    [Abstract] [Full Text] [Related]

  • 15. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties.
    Lesueur-Ginot L, Demarquay D, Kiss R, Kasprzyk PG, Dassonneville L, Bailly C, Camara J, Lavergne O, Bigg DC.
    Cancer Res; 1999 Jun 15; 59(12):2939-43. PubMed ID: 10383158
    [Abstract] [Full Text] [Related]

  • 16. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
    Minderman H, Wrzosek C, Cao S, Utsugi T, Kobunai T, Yamada Y, Rustum YM.
    Cancer Chemother Pharmacol; 2000 Jun 15; 45(1):78-84. PubMed ID: 10647506
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
    Thapa P, Karki R, Choi H, Choi JH, Yun M, Jeong BS, Jung MJ, Nam JM, Na Y, Cho WJ, Kwon Y, Lee ES.
    Bioorg Med Chem; 2010 Mar 15; 18(6):2245-2254. PubMed ID: 20188578
    [Abstract] [Full Text] [Related]

  • 18. Camptothecin and minor-groove binder hybrid molecules: synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro.
    Zhao R, al-Said NH, Sternbach DL, Lown JW.
    J Med Chem; 1997 Jan 17; 40(2):216-25. PubMed ID: 9003520
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
    Lee JH, Lee JM, Kim JK, Ahn SK, Lee SJ, Kim MY, Jew SS, Park JG, Hong CI.
    Arch Pharm Res; 1998 Oct 17; 21(5):581-90. PubMed ID: 9875499
    [Abstract] [Full Text] [Related]

  • 20. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
    Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC.
    J Med Chem; 1998 Dec 31; 41(27):5410-9. PubMed ID: 9876111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.